SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on December 15, 2025 it granted stock options to purchase an aggregate of 21,399 shares of common stock and 14,422 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 10 employees, whose employment commenced in November and December 2025 as a material inducement to their employment.The RSUs will vest over 3 years, with 40% of the RSUs vesting o ...

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization in the European Union (EU) for MYQORZO® (aficamten), a cardiac myosin inhibitor, for the treatment of symptomatic (New York Heart Association, NYHA, class II-III ...

What happenedForesite Capital Management IV, LLC disclosed a new stake in Cytokinetics (CYTK 2.28%), adding 458,295 shares valued at $25.19 million as of Sept. 30, 2025. The move was detailed in a quarterly report filed with the U.S. Securities and Exchange Commission on Nov. 14, 2025 (SEC filing). The fund’s total reportable U.S. equity assets stood at $182.61 million across six holdings after the filing.What else to knowThis is a new position for Foresite Capital Management IV, LLC, representing 13.8% of ...

A month has gone by since the last earnings report for Cytokinetics (CYTK) . Shares have added about 10.4% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Cytokinetics due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Cytokinetics, Incorporated before we dive into how investors and analysts have reacted as of late.Cytokinetics ...

While Cytokinetics ( CYTK ) investors go through the ups and downs surrounding the aficamten PDUFA event , let's not forget that aficamten is only a small part of the company - the forward flank, if you will. Behind itDubai-based investor focused on building a resilient, income-generating portfolio with a long-term growth mindset. My approach is primarily long-only, blending dividend-paying equities, REITs, and other income strategies with selective growth opportunities. I believe in disciplined, fundamenta ...

Core Points - Rosen Law Firm is reminding purchasers of Cytokinetics, Inc. common stock about the lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the Class Period from December 27, 2023, to May 6, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Cytokinetics common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 17, 2025 [3]. - The lawsuit alleges that Cytokinetics made false and misleading statements regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten, specifically regarding expected FDA approval in the second half of 2025 [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a record settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4].

Core Insights - Cytokinetics is under investigation for potentially misleading investors regarding the regulatory timeline for their drug aficamten, particularly concerning the absence of a Risk Evaluation and Mitigation Strategy (REMS) in their New Drug Application (NDA) [1][2] Company Developments - During a May 6, 2025 earnings call, Cytokinetics disclosed multiple pre-NDA meetings with the FDA but submitted the NDA without a REMS, which misled investors and inflated stock prices [2] - On November 11, 2025, Kaye Edward M. MD, a director at Cytokinetics, sold 5,175 shares at $65.08 each, retaining 9,977 shares [3] - The stock price has fluctuated between $65.33 and $67.98, with a current price of $67.06, reflecting a slight increase of 0.93% or $0.62 [3][4] Market Performance - Cytokinetics has a market capitalization of approximately $7.98 billion, with a trading volume of 813,094 shares [4] - The stock's lowest price in the past year was $29.31, indicating significant volatility [4]

New York, New York--(Newsfile Corp. - November 17, 2025) - If you suffered a loss on your Cytokinetics, Incorporated (NASDAQ: CYTK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/cytokinetics-incorporated-lawsuit-submission-form-2?prid=177791&wire=5&utm_campaign=7or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced sharehol ...

CYTK DEADLINE: ROSEN, GLOBAL INVESTOR RIGHTS COUNSEL, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important November 17 Deadline in Securities Class Action - CYTKNovember 17, 2025 1:44 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (th ...

Share Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK--(BUSINESS WIRE)--Faruqi & Fa ...